There has been a sustained increase in SARS-CoV-2 variants that are resistant to monoclonal antibody bamlanivimab. Therefore, the USFDA has revoked the emergency use authorization (EUA) of bamlanivimab to prevent any risk of treatment failure. The USFDA has revoked the emergency use authorization (EUA) for the monoclonal antibody therapy, bamlanivimab when administered alone.
Recent data suggest that a sustained increase in the SARS-CoV-2 variants resistant to bamlanivimab alone has increased the risk for treatment failure. Since the known and potential risks associated with the use of bamlanivimab alone far outweigh the potential benefits associated with its authorized use, the FDA has taken this decision to revoke its EUA status. However, alternate monoclonal antibody therapies such as coadministration of bamlanivimab and etesivimab or casirivimab and imdevimab can be administered to…
